Prestige Consumer Healthcare Inc. surpassed sales and earnings expectations in Q2 fiscal 2026, driven by Clear Eyes® supply timing and retailer orders. The company maintained its financial profile and repurchased shares, while reaffirming its fiscal 2026 revenue outlook and updating its Adjusted Diluted EPS outlook to the high end of the previous range.
Revenue for Q2 fiscal 2026 was $274.1 million, exceeding outlook.
Diluted EPS was $0.86, and Adjusted Diluted EPS was $1.07.
Approximately 1.1 million shares were repurchased opportunistically in Q2.
Fiscal 2026 revenue outlook remains unchanged, while Adjusted Diluted EPS outlook was updated to $4.54 to $4.58, the high end of the previous range.
For fiscal year 2026, Prestige Consumer Healthcare Inc. reaffirms its net sales outlook and updates its Adjusted Diluted EPS outlook to the higher end of the previous range, driven by strong financial profile and share repurchases.
Visualization of income flow from segment revenue to net income